Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,308.81 +4.09 (+0.08%) Dow
38,942.55 -127.04 (-0.33%) Nasdaq
17,000.42 +79.62 (+0.47%) Bitcoin USD
67,874.41 -1,224.01 (-1.77%) CMC Crypto 200
1,477.86 -18.59 (-1.24%)
LLY Dec 2025 220.000 call
| Previous close | 524.75 |
| Open | 524.75 |
| Bid | 551.00 |
| Ask | 561.00 |
| Strike | 220.00 |
| Expiry date | 2025-12-19 |
| Day's range | 524.75 - 524.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 139 |
PR NewswireLilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA, will participate in a fireside chat at 4 p.m. Eastern time.
ZacksEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ReutersAnalysis-Weight-loss drug forecasts jump to $150 billion as supply grows
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.
